NEUARTIGE THERAPIE

European patent · EP3277813 · In force

Register entry

Publication number
EP3277813
Application number
EP16715897
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Mar 24, 2016
Published
Feb 7, 2018
Granted
Sep 16, 2020
Protection ends at the latest
Mar 23, 2036
Next annual fee due
Mar 31, 2027
IPC classes
C12N 15/113 (2010.01)
A61K 31/713 (2006.01)
Priority
GB 201505382 29.03.2015
PCT application
PCT/IB2016/051674 24.03.2016
PCT publication
WO2016/157044 06.10.2016
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Apr 1, 2026

    Change

    Published in Swissreg on 01.04.2026

  2. Apr 1, 2025

    Change

    Published in Swissreg on 01.04.2025

  3. Apr 1, 2024

    Change

    Published in Swissreg on 01.04.2024

  4. Apr 26, 2023

    Change

    Published in Swissreg on 26.04.2023

  5. Apr 16, 2021

    Transferred

    Owner
    Linnane Pharma AB, Slottsgatan 32, 21133 Malmo, Sweden → Selectimmune Pharma AB, Klinikgatan 32, 22242 Lund, Sweden

    Published in Swissreg on 16.04.2021

  6. Dec 23, 2020

    Agent entered

    Representative
    Latscha Schöllhorn Partner AG, Grellingerstrasse 60, 4052 Basel

    Published in Swissreg on 23.12.2020

  7. Sep 16, 2020

    Granted

    Published in Swissreg on 16.09.2020

Parties

Holder

Selectimmune Pharma AB

Klinikgatan 32, 22242 Lund, SE

Agent

Latscha Schöllhorn Partner AG

Grellingerstrasse 60, 4052 Basel

Inventor

PUTHIA, Manoj

S-223 62 Lund, SE

SVANBORG, Catharina

21133 Malmo, SE

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.